Background Triple-negative breast cancer (TNBC) subtypes are clinically aggressive and cannot be treated with targeted therapeutics commonly used in other breast cancer subtypes. The claudin-low (CL) molecular subtype of TNBC has high rates of metastases, chemoresistance and recurrence. There exists an urgent need to identify novel therapeutic targets in TNBC; however, existing models utilized in target discovery research are limited. Patient-derived xenograft (PDX) models have emerged as superior models for target discovery experiments because they recapitulate features of patient tumors that are limited by cell-line derived xenograft methods. Methods We utilize immunohistochemistry, qRT-PCR and Western Blot to visualize tumor architecture, cellular composition, genomic and protein expressions of a new CL-TNBC PDX model (TU-BcX-2O0). We utilize tissue decellularization techniques to examine extracellular matrix composition of TU-BcX-2O0. Results Our laboratory successfully established a TNBC PDX tumor, TU-BCX-2O0, which represents a CL-TNBC subtype and maintains this phenotype throughout subsequent passaging. We dissected TU-BCx-2O0 to examine aspects of this complex tumor that can be targeted by developing therapeutics, including the whole and intact breast tumor, specific cell populations within the tumor, and the extracellular matrix. Conclusions Here, we characterize a claudin-low TNBC patient-derived xenograft model that can be utilized for therapeutic research studies.
Background
Triple-negative breast cancers (TNBCs) have more aggressive phenotypes than other breast cancer subtypes, with higher rates of metastasis, recurrence, and development of chemoresistance [1, 2] . Due to reduced expression of commonly targeted receptors (estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2)), TNBCs are more difficult to treat compared to other breast cancer subtypes, underlining the need to discover novel therapeutic targets in TNBC [3] [4] [5] . TNBCs are categorized into four molecular subtypes: basal-like (BL1 and BL2), mesenchymal (M) and luminal androgen receptor (LAR) [6] . Each subtype has a distinct molecular profile, which dictates responsiveness (or sensitivity) to targeted therapies and immune infiltration [7, 8] . Within the basal-like subtypes, there exists an intrinsic tumor cell population that expresses low levels of luminal differentiation markers, higher expression of genes associated with epithelial-to-mesenchymal transition (FN1, MMP2, TWIST, SERPINE1, THY1, SPARC) [9] and is enriched in genes involved in the immune response and 1 3 cancer stem cell (CSC) populations [10, 11] . This subpopulation of basal-like tumors is known as claudin-low TNBC (CL-TNBC). On a transcriptional level, CL-TNBCs exhibit high genomic instability and are highly undifferentiated. Clinically, CL-TNBCs have high rates of metastasis, recurrence and chemoresistance [8] . The recent classification of the CL subtype revealed unchartered approaches to identify targets that are specific for the different molecular subtypes [12] . Notably, the CL subtype is the least characterized molecular TNBC subtype in the literature.
One obstacle in the field of drug discovery research includes limitations of frequently utilized xenograft models. Many of these models, namely immortalized cell lines in vitro and the subsequent in vivo cell line-derived orthotopic xenografts, do not re-create patient-specific features of tumors. More specifically, these models cannot accurately reflect the tumor architecture and surrounding stroma, and cannot reproduce the cellular heterogeneity that is present in the original patient tumor [13] [14] [15] . Passaging of immortalized cell lines results in the introduction of irreversible alterations in genetic information and behavioral characteristics [16] . Bypassing these obstacles is crucial to investigating previously unrecognized targets and mechanisms of neoplastic diseases beyond breast cancer.
Patient-derived xenografts (PDXs) are emerging as a novel research models that overcome these limitations [17] [18] [19] . Therapeutic discovery in breast cancer can especially benefit from these translational models because the resulting xenografted tumor explants consistently that maintain the complex stromal architecture and heterogeneous cellular composition of TNBC [20] [21] [22] . Furthermore, PDX models facilitate studying mutations and drug interactions that are specific to TNBC subtypes that have a specific molecular signature [23] [24] [25] . In fact, PDX models have been found to accurately reflect clinical response to therapeutic agents [26] . One disadvantage to the PDX model is that over time, after multiple passages in mice, murine components invade the tumor and there is evidence of loss of human stromal architecture of the tumors. However, the genomic profiles and clonal dynamics of breast cancer PDX tumors can remain stable throughout sequential in vivo passages [27, 28] .
Therapeutic discovery research benefits from the preservation of the tumor microenvironment from the patient, including stromal architecture and stromal cells, sub-populations of tumor cells, extracellular matrix components and interactions amongst diverse cell types. Together, investigating how compounds affect various aspects of the tumor strengthens drug discovery experiments to optimize treatment strategies of CL-TNBCs. In this study, we have established and characterized a TNBC PDX model that represents the mesenchymal, claudin-low TNBC subtype based on genomic profiles, composition and tumor architecture.
We believe that the use of these translational PDX models will help identify and characterize new molecular targets involved in tumorigenesis and formation of metastases that will ultimately reveal patient-specific therapies.
Materials and methods

Reagents
Dulbecco's modified Eagle's medium (DMEM), Dulbecco's phosphate-buffered saline (PBS), phenol red-free DMEM, fetal bovine serum (FBS), essential amino acids, non-essential amino acids (NEAA), antibiotic/anti-mitotic, penicillin/ streptomycin, sodium pyruvate, and EDTA (0.5 M, pH 8) were obtained from GIBCO (Invitrogen; Carlsbad CA). Insulin was purchased from Sigma-Aldrich (St. Louis MO) and charcoal-stripped FBS from HyClone (Thermo Scientific; Logan UT). Dimethyl sulfoxide (DMSO) was obtained from Research Organics, Inc (Cleveland OH).
Cell culture
Human MDA-MB-231 cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and are characterized as triple-negative/basal B mammary carcinoma. Cells were maintained in DMEM supplemented with 10% FBS, NEAA, MEM amino acids, anti-anti (100 U/ mL), sodium pyruvate and porcine insulin (1 × 10 −10 mol/L) at 37 °C in humidified 5% CO 2 . For treatment studies, cells were grown in phenol red-free DMEM supplemented with 5% charcoal-stripped FBS and supplemented with NEAA, MEM amino acids, Gluta-Max and penicillin (100 U/mL). and implanted bilaterally into the mammary fat pads (mfp) of mice under isoflurane and oxygen. Tumors were measured using a digital caliper after ostensible tumor take was established. Tumors were passaged when tumor volume achieved 750-1000 mm 3 . To passage, mice were euthanized by CO 2 and tumors were removed, dissected, coated in full factor Matrigel, and then implanted bilaterally into other SCID/Beige mice that were anesthetized using a mix of isoflurane and oxygen delivered by mask. Before surgery, mice were given Meloxicam (5 mg/kg/day, for 3 days' post-surgery) for pain.
Patient-derived xenografts
RNA isolation and quantitative real-time PCR
MDA-MB-231 cells were plated in 10% DMEM and grew to 70% confluency. Cells were harvested and total RNA was isolated using RNeasy (Qiagen, Valencia, CA) following manufacturer's protocol; quantity and quality were determined by absorbance (260, 280 nm). Total RNA (2 µg) was reverse-transcribed (iScript kit, BioRad Laboratories, Hercules, CA) and analyzed by qRT-PCR. All qRT-PCR data were normalized to actin. Primer sequences are as follows (Invitrogen, Carlsbad, CA): β-actin F-5′-GGC ACC CAG CAC AAT GAA GA-3′; β-actin R-5′-ACT CCT GCT TGC TGA TCC AC-3′; CDH1 F-5′-AGG TGA CAG AGC CTC TGG ATAGA-3′, CDH1 R-3′-TGG ATG ACA CAG CGT GAG AGA-3′. CDH2 F-5′-GCC CCT CAA GTG TTA CCT CAA-3′; CDH2 R-5′-AGC CGA GTG ATG GTC CAA TTT-3′, SNAIL F-5′-ACC ACT ATG CCG CGC TCT T-3′; SNAIL R-5′-GGT CGT AGG GCT GCT GGA A-3′, ZEB1 F-5′-ACA CAA GCG AGA GGA TCA TG-3′; ZEB1 R-5′-CGG AAT CTG AAT TTG CTT CTACC-3′, FRA1 F-5′-AGC TGC AGA AGC AGA AGG AG-3′; FRA1 R-5′-GGG GAA AGG GAG ATA CAA GG-3′; PLAU F-5′-GGT GAC GCC TTC AGC ATG A-3′; PLAU R-5′-CCC ACT GCG GTA CTG GAC AT-3′. qRT-PCR was conducted as previously published [29] . Data were represented as normalized fold expression compared to human actin with biological triplicate samples ± SEM.
Immunohistochemistry staining
Formalin-fixed, paraffin-embedded tumor sections were deparaffinized, rehydrated in a graded solution of Sub-X solutions, stained with hematoxylin and eosin or quenched with 0.3% H 2 O 2 (Sigma-Aldrich, St. Louis MO), rinsed with PBS with Triton X-100 (PBST), blocked with 1% BSA and stained with primary antibodies against Ki-67 (Abcam) overnight at 4 °C. Each tumor section was subsequently washed in PBST, incubated with appropriate HRP-conjugated secondary antibody, and washed with PBST. For colorimetric staining, slides were then incubated in 3,3′-diaminobenzidine (DAB; Vector Laboratories; Burlingame, CA, USA), washed with PBST, counterstained with hematoxylin, and rinsed with deionized water. Slides were sealed with Permount Mounting Medium (Sigma). Images were acquired at 10X, 20X and 40X objectives using an Aperio Scanscope instrument (Aperio Technologies, Inc., Vista, CA, USA) with ImageScope software (Aperio Technologies, Inc).
Immunofluorescence staining
For immunofluorescence staining, paraffin-embedded tissue sections were stained according to the standard protocol of LSUHSC Molecular Histopathology and Analytical Microscopy core. Briefly, tissue sections were deparaffinization in xylene, re-hydration through descending grades of alcohol to water, non-enzymatic antigen retrieval in citrate buffer, followed by PBS wash and then blocking. Sections were then incubated with a first primary antibody overnight at room temperature, rinsed in PBS and a fluorescein-conjugated secondary antibody (1:200 dilution; Invitrogen) was added and incubated for an hour in the dark. After washing with PBS, a second primary antibody was added overnight in the dark, followed by rinsing with PBS and incubation with a second rhodamine-tagged secondary antibody (1:200 dilution; Invitrogen) for an hour. Primary antibodies included mouse monoclonal antibodies against CD11b (1:50 dilution; Abcam), rat monoclonal Gr-1 (1:100 dilution; Abcam), rabbit polyclonal CD68 (1:100 dilution; Abcam), and rabbit polyclonal F4/80 (1:100 dilution; Abcam). Sections were then washed in PBS, mounted with DAPI (Vector Laboratories), and analyzed using a confocal microscope (Olympus FV1000).
Flow cytometry
Tumors were digested with DNAse and Liberase (Roche) at 37 °C for 1 h, and tumor-infiltrating MDSC were isolated from tumor single-cell suspensions as described [32] . The following fluorochrome-conjugated human antibodies were used to characterize cell subtypes: CD33 (WM53), HLA-DR (G46-6), CD68 (Y1/82A) (all from BD Biosciences) and CD14 (61D3; eBioscence). Fluorochrome-conjugated mouse antibodies specific for CD11b (M1/70), Gr1 (RB6-8C5), Ly6C (AL-21), and Ly6G (1A8) were purchased from BD Biosciences. Live/Dead cell staining kit was from Molecular Probes (Life Technologies).
PDX decellularization and histological analysis
PDX tumors were decellularized through a modified protocol previously described [30, 31] . In brief, tumor samples were collected and left in water for 24 h at 4 °C followed by incubation in Triton X-100 (Bio-Rad, Hercules CA, Cat. No. 1610406). Cells were first washed in deionized water and incubated in sodium deoxycholate solution (Thermo Fisher Scientific, Waltham MA), then washed in deionized water and incubated in calcium chloride (Sigma-Aldrich, St. Louis MO) and finally washed with deionized water and treated with DNAse I (1 U/mL, Sigma-Aldrich, St. Louis MO) and antibiotic-antimycotic (100 U/mL; ThermoFisher Scientific, Waltham MA) solutions. Decellularized tumors were then formalin-fixed (10%), paraffin-embedded and sectioned for Picosirius Red staining. Total collagen content was observed through 4X objective on an Olympus BX51 system microscope. Analysis of collagen fibers was performed in Matlab with a custom code. Quantification of collagen I:III and subsequent representative darkfield images were obtained through use of polarized light microscopy, as described previously [32] .
Statistical analysis
Studies run in triplicates were analyzed by unpaired Student's t test (Graph Pad Prism V.4). p-Values < 0.05 were considered statistically significant. The flow cytometry analysis of the circulating tumor cells was run in duplicates; all other analyses were run in triplicates.
Results
Characterization of TU-BcX-2O0
TU-BcX-2O0 was derived from a 70-year-old AfricanAmerican female diagnosed with non-metastatic, Grade 3 invasive ductal carcinoma. Pathology reported the PAM50 subtype to be TNBC (Fig. 1a) . Before implantation in SCID/beige mice, we coated TU-BcX-2O0 in Matrigel to mimic the extracellular matrix of the tumor microenvironment. After 102 days, the primary tumor grew to a measurable size, and another 49 days for the tumor to grow to our endpoint volume, 750-1000 mm 3 . Tumors were propagated for future ex vivo and in vitro experiments. In gross appearance, both the primary tumor and subsequent passages had nodules on the surface of the tumor that appeared "pustulate-like" (Fig. 1b) . As , not yet engrafted into SCID/beige mice) histology was compared to lower (T2) and higher passage (T5) PDX tumors. H & E stained images were captured at 10X, 20X and 40X. e Proliferation rate determined by Ki-67 immunohistochemistry staining of TUBcX-2O0T5 PDX tumor compared to negative control expected, both time to tumor palpation after engraftment and tumor growth were highest in the initial passages compared to consecutive passages. (Fig. 1c) .
Formalin-fixed paraffin-embedded sections of primary tumor and subsequent xenograft passages were stained with Hematoxylin and Eosin (H&E) for microscopic evaluation. The histologic appearances of all tumors, primary as well as low and high passages, were similar and revealed high-grade histology represented by highgrade nuclei, lack of tubule formation and numerous mitoses including atypical mitotic figures, and areas of extensive tumor necrosis (Fig. 1d) . Furthermore, in concordance with the Pathology report, TU-BcX-2O0 tumors revealed high proliferation rate by immunohistochemical staining with Ki-67 antibody (Fig. 1e) . H&E staining also revealed abundant presence of mixed inflammatory components, namely neutrophils, lymphocytes and eosinophils, although they were restricted to the periphery of the tumor (Supplementary Fig. S1 ). CL-TNBC tumors have an enriched immune response [7] , and we found increased mRNA expression of CXCL2 compared to IL-6, IL-8 and CXCR4 (Supplementary Fig. S2a ). Further, TU-BcX-2O0 had similar mRNA expression of CL-TNBC specific immune genes (CD79A, CD79B, CD14, VAV1 and CXCL12) compared to MDA-MB-231 cells [12, 33] (Supplementary Fig. S2b ). Gr-1 + CD11b + cells, or immune suppressive myeloid-derived suppressor cells (MDSCs), are overproduced in tumor-bearing mice, in both the peripheral blood and spleens. A population of these MDSCs were found within the TUBcX-2O0 tumor ( Supplementary Fig. 3a ). Human macrophages, CD68 + cells, were present both in initial and even in higher passages. Mouse macrophages, identified as F4/80 + cells, were not observed in neither low nor higher passages (Supplementary Fig. S3b ). These data were confirmed by flow cytometry; the immune composition of the blood and spleen were also analyzed. There was a higher population of mouse MDSCs and macrophages in the blood and spleen compared to the tumor. Further, there were fewer circulating MDSCs (CD11b + Gr1 + ) and macrophages (CD11b + F4/80 + ) in tumor-bearing mice than in normal mice, suggestive of the possible migration of these immune subsets from the periphery into the tumor site. It is also of note that the percentages of polymorphonuclear MDSCs (CD11b + Gr1 + Ly6C low Ly6G + ) were higher than those of monocytic MDSCs (CD11b + Gr1 + Ly6C high Ly6G − ) in all organs ( Supplementary Figs. 4 and 5) . Finally, the presence of human myeloid cells (CD33 + HLA-DR − ) in TUBcX-2O0 detected by immunohistochemistry was confirmed with flow cytometry data ( Supplementary Fig. 5 ). The fact that these cells are HLA-DR − may indicate their immunoregulatory nature.
Molecular characterization of TU-BcX-2O0
TU-BcX-2O0 forms metastatic lesions in the lungs of SCID/ beige mice in both low and high passages, with larger and more frequent lesions in the lower passages (Fig. 2a) . To evaluate the molecular characteristics of TU-BcX-2O0 over consecutive passages, we analyzed mRNA expression of both luminal and mesenchymal genes in explants using qRT-PCR. While we found evidence of low endogenous levels of the luminal marker E-cadherin (CDH1), there were slightly higher levels of other luminal-associated genes EpCAM and CD24. Of the basal markers analyzed, there were high levels of endogenous VIM expression, and high levels of CDH2, cFOS, TWIST, SNAI1 and SNAI2 mRNA expression in TU-BcX-2O0. These data suggest a "basal-like" phenotype of TU-BcX-2O0 which was consistent throughout passages (Fig. 2b) . Next, to refine our characterization of the molecular subtype of this TNBC tumor, we analyzed relative claudin (CLDN) expression of the tumors. Specifically, we chose CLDN 3, 4 and 7 because these specific claudins define the "claudin-low" TNBC phenotype. We compared the results to a known CL-TNBC cell line, MDA-MB-231, to observe relative expression. CLDN3 expression was most similar to MDA-MB-231 in both low and high passage TU-BcX-2O0. CLDN4 mRNA expression was lower in TU-BcX-2O0 compared to MDA-MB-231 in both low and high passage. CLDN7 was elevated compared to MDA-MB-231 in low passage, but not higher passage tumors (Fig. 2c) . Then we evaluated mRNA expression of MUC1, which is also downregulated in CL-TNBC phenotype. We observed similar endogenous mRNA expression as that in MDA-MB-231 cells (Fig. 2d) . Low expression of MUC1 protein was confirmed with the Alcian Blue stain (Supplementary Fig. S7 ).
Collagen composition of TU-BcX-2O0
To evaluate the relative collagen composition, we stained sections of paraffin-embedded tumor with Picosirius Red to highlight collagen fibers, and then use polarized light to examine collagen bundles. Collagen I is represented by red or orange, and collagen III is represented by yellow or green. Using this method, the collagen composition of tumors can be quantified [34] . We show that in both lower and higher passages, TU-BcX-2O0 has a higher expression of collagen I compared to minimal expression of collagen III (Fig. 3a) . Then, because recent therapeutic discovery research is invested in evaluating roles of novel therapeutics on the extracellular environment, we stripped the tumor of its cellular components using a novel decellurization method to evaluate relative collagen composition without the background of active cell signaling. Decellurization of TU-BcX-2O0 resulted in a similar ratio of collagen I to collagen III, albeit with lower expression levels of collagen type I (Fig. 3b) .
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Finally, quantification of these data show significant differences between lower and higher collagen I:III ratio in low versus higher passage, although this is due to less intensity of collagen I density, and not due to an increase in collagen III (Fig. 3c) . These results are reflected in the decellularized tumor: There were significant changes between passages of decellularized TU-BcX-2O0, although this was also due to reduced intensity of collagen I density and not due to an increase in collagen III (Fig. 3d) .
Discussion
In this study, we describe a novel PDX model that represents the claudin-low TNBC molecular subtype. We demonstrate the value of using translational PDX models in target discovery and therapeutic research, especially in complex tumors such as the claudin-low TNBC subtype. In gross appearance, TU-BcX-2O0 has pustulate-like nodules and areas of liquefactive necrosis. Based on these observations, and our knowledge that the CL-TNBC subtype elicits immune infiltrates more than other subtypes, we investigated TU-BcX-2O0 as a claudin-low TNBC tumor. Claudin-low TNBCs are similar to basal subtypes but have distinctive biological and molecular signatures. They undifferentiated and enriched in epithelial-to-mesenchymal and stem celllike markers. We first show that TU-BcX-2O0 consistently metastasized to the lungs. Gene expression analyses confirmed endogenous levels of some mesenchymal markers and low expression of epithelial markers. These findings confirm that TU-BcX-2O0 has a mesenchymal phenotype and is capable of spontaneous metastasis. Compared to basal subtypes, CL-TNBC tumors have very low expression of cell-cell adhesion molecules, including E-cadherin, claudins (specifically CLDN3, CLDN4 and CLDN7) and MUC-1, which contributes to the propensity of this tumor subtype to metastasize. We compared claudin gene expression of the TU-BcX-2O0 to a previously established CL-TNBC cell line, MDA-MB-231 [35] . Notably, endogenous mRNA expressions of CLDN3 and CLDN7 in TU-BcX-2O0-resembled MDA-MB-231, while CLDN4 mRNA expression was significantly lower in TU-BcX-2O0. These data were The extracellular matrix is another aspect of the tumor microenvironment that has been investigated as a therapeutic target, specifically the collagen networks that surround tumor cells. Although collagens have a diverse role in breast cancer tumorigenesis and metastasis, two collagen subtypes have been identified to predict breast cancer invasiveness. Collagen type I is associated with increased invasiveness and recruitment of stromal cells and other microenvironment components and is increased in metastatic subtypes. Conversely, collagen type III suppresses invasive potential of breast cancer cells. To analyze the collagen composition of the tumor in the absence of cell signaling interference, we utilized a novel technique to decellularize the tumor tissue, then we used Picosirius Red staining under polarized light to quantify the relative composition of collagen subtypes. We found that in both TU-BcX-2O0 natural tumor and the decellularized tumor, there was dramatically higher expression of collagen type I compared to collagen type III, indicating TU-BcX-2O0 has an extracellular matrix that has a higher invasive potential. These data show that TU-BcX-2O0, as well as the associated decellularized model, can be utilized for novel therapeutic target discovery, to evaluate how therapeutics affects collagen composition. We will interrogate this concept in future studies.
Due to the unique gross appearance of TU-BcX-2O0 tumor with the cutaneous areas of pustulate, we evaluated immune-related components of the tumor. Tumor-associated neutrophils and macrophages have been observed in 50% of the total tumor mass in invasive breast carcinomas [36] . Tumor cells drive local neutrophil recruitment and the presence of intratumoral neutrophils has been shown to increase invasive capacity and drive angiogenesis of breast cancer cells [36] . In our data, we did identify a presence of mouse Gr-1 + myeloid cells as well as CD11b+ cells within the tumor. CD11b is involved in recruitment of tumor-associated macrophages (TAMs) to tumors which remodel the microenvironment to promote tumorigenesis and contribute to formation of the pre-metastatic niche [36] . Interestingly, we also discovered a significant human macrophage infiltration that was consistent in both low and high passages. CD11b + GR-1 + mouse MDSCs were present, a cell type that promotes tumorigenesis and metastasis by contributing significantly to tumors' ability to escape from immune surveillance [37] . Characteristically, CL-TNBC tumors have higher baseline expressions of immune response genes including CD79A, CD79B, VAV1, CD4, CXCL2, CXCR4 and CD14 [12] as well as several cytokines that cytokines Fig. 3 Collagen composition of TU-BcX-2O0 was not altered throughout consecutive passages. a Picosirius Red staining (top panel) was utilized to highlight collagen fibers, and subsequent imaging of the stained slides under filtered light (bottom panels) revealed specific collagen I and collagen III composition of tumors throughout low and higher passages. Also shown are extracted images of the four polarized filters utilized to identify the specific collagens displayed. Red and orange filter indicate collagen I; yellow and green indicate presence of collagen III. b Similar architecture is shown when the tumor was decellularized. There is an abundance of collagen I compared to collagen III. c Quantification of collagen staining demonstrates collagen I:III ratio was larger in lower passage TU-BcX-2O0 compared to higher passage, although collagen III staining remained low (p = 0.0093). d Additionally, in decellularized TU-BcX-2O0 tumor, there was a significant variation of collagen I:III ratio between passages (p = 0.002), although collagen I remained dominant. Quantification was performed in triplicates and ratio is shown as Red AF + Orange AF/Yellow AF + Green AF; AF denotes Area Fraction (%). n = 3 for TU-BcX-2O0T3 decellularized and TU-BcX-2O0T5; n = 4 for 2O0T0 and n = 5 for TU-BcX-2O0T4 decellularized TUBcX-2O0 promote tumor immune infiltration and angiogenesis (IL-8) and stimulate the growth of TNBC cells [38, 39] . The TUBcX-2O0 model may be useful to investigate the role of various therapeutics on the cross-talk between CL-TNBC and myeloid cells mediated by CXCL2 and other factors. An important limitation of non-humanized PDX models is that immunocompromised mouse strains such as the SCID/ beige strain used in our xenograft experiments lacks T-cells and B-cells, and impairs NK-cell development.
Claudin-low TNBCs remain elusive to small molecule targeted therapies, especially due to the complex microenvironment of the CL-TNBCs and the tumor cell's interactions with surrounding cellular and stromal components. We demonstrate in our study various applications of utilizing PDX models in therapeutic discovery research. There are many advantages to creating a novel claudin-low cell line derived from PDX tumors. This cell line bypasses common limitations of immortalized cell lines or cell lines that have been used for multiple passages. Over time, cell lines acquire mutations, and are altered by the stress of repeated passaging; this can drastically alter results, especially in drug discovery experiments and cytotoxicity studies. Our establishment of a TU-BcX-2O0 cell line creates a new tool to study the biology of CL-TNBC tumors in a model that has not undergone multiple in vitro passages. Furthermore, the PDX tumor is derived from a post-menopausal African-American patient, a population that has higher rates of TNBC mortality. Louisiana has a high proportion of African-American residents (32.5% in 2015), and the incidence of TNBC in New Orleans is among the highest in the US [40] [41] [42] . The application of this model in therapeutic discovery may facilitate more extensive studies on this subset of cancers.
Conclusions
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